Oncolytics Biotech Inc. Stock News

Bet on top-ranked stocks STKL, LZB, ONCY, TPR and TRVI that have rising P/E to realize outsized gains.

Oncolytics Biotech Inc. (ONCY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreem

Bet on top-ranked stocks STKL, LZB, ONCY, TPR and TRVI that have rising P/E to realize outsized gains.

Renaissance Technologies LLC acquired a new stake in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) in the second quarter, Holdings Channel reports. The fund acquired 23,000 shares of the companys stock, valued at approximately $64,000. A number of other hedge funds have also recently bought and sold shares of the business. JPMorgan Chase & Co. lifted []

Zacks Investment Research upgraded shares of Oncolytics Biotech (NASDAQ:ONCY) from a hold rating to a buy rating in a report published on Thursday morning, Zacks.com reports. Zacks Investment Research currently has $2.00 target price on the stock. According to Zacks, Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment []

Oncolytics Biotech Inc. (NASDAQ:ONCY)s traded shares stood at 0.32 million during the last session, with the companys beta value hitting 2.65. At the close of trading, the stocks price was $1.74, to imply a decrease of -0.57% or -$0.01 in intraday trading. The ONCY shares 52-week high remains $4.83, putting it -177.59% down since that Boom Or Bust: What Are Oncolytics Biotech Inc.s (NASDAQ:ONCY) Future Prospects? Read More »

Oncolytics Biotech Inc. (ONCY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earn

IRENE study is evaluating pelareorep-anti-PD-1 combination treatment in metastatic TNBC SAN DIEGO and CALGARY, AB, Nov. 19, 2021 /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) t

Oncolytics Biotech Inc. (ONCY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earn

IRENE study is evaluating pelareorep-anti-PD-1 combination treatment in metastatic TNBC SAN DIEGO and CALGARY, AB, Nov. 19, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) to

Newman Dignan & Sheerar Inc. acquired a new position in Oncolytics Biotech Inc. (NASDAQ:ONCY) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,915 shares of the companys stock, valued at approximately $27,000. Other large investors have also modified their holdings of the []

Oncolytics Biotech Inc. (ONCY) CEO Matt Coffey on Q3 2021 Results - Earnings Call Transcript

SAN DIEGO and CALGARY, AB, Oct. 19, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, November 5, 202

Trial is designed to advance pelareorep's clinical development in China, the world's second-largest pharmaceutical market SAN DIEGO and CALGARY, AB, Oct. 14, 2021 /PRNewswire/ -- Oncolytics Biotech®�

The heavy selling pressure might have exhausted for Oncolytics Biotech Inc. (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall St